Home » Stocks » VSTM

Verastem, Inc. (VSTM)

Stock Price: $2.88 USD 0.03 (1.05%)
Updated May 10, 2021 3:12 PM EDT - Market open
Market Cap 489.25M
Revenue (ttm) 88.52M
Net Income (ttm) -67.73M
Shares Out 153.33M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $2.88
Previous Close $2.85
Change ($) 0.03
Change (%) 1.05%
Day's Open 2.82
Day's Range 2.79 - 2.92
Day's Volume 1,404,869
52-Week Range 1.08 - 3.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...

Other stocks mentioned: ADMA, BOXL
1 week ago - PennyStocks

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fi...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

2 months ago - Business Wire

The biotech's chief medical officer has stepped down just two weeks after joining the company.

3 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

3 months ago - Business Wire

Verastem has recently raised non-dilutive capital to bring two assets into phase 2 trials. The company's lead asset has the potential to address around 30% of all cancers and be combined with other medi...

3 months ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

4 months ago - Business Wire

Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.

5 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fin...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced ne...

6 months ago - Business Wire

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced up...

7 months ago - Business Wire

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...

7 months ago - Business Wire

The biotech company reported second-quarter earnings and sold some drug development rights.

8 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...

9 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

9 months ago - Business Wire

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Verastem: A Growth Story In The Biotechnology Sector

9 months ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...

10 months ago - Business Wire

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.

1 year ago - The Motley Fool

Is (VSTM) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.

1 year ago - The Motley Fool

Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.

Other stocks mentioned: AGEN, DVAX
1 year ago - The Motley Fool

Investors are excited about an upcoming conference call to discuss clinical data from patients with KRAS-mutation positive tumors.

1 year ago - The Motley Fool

Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

1 year ago - Zacks Investment Research

Verastem Oncology: An Undervalued KRAS Oncology Play

1 year ago - Seeking Alpha

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, AMRX, MRTX, VKTX
1 year ago - The Motley Fool

Is (VSTM) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Verastem has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).

1 year ago - Zacks Investment Research

Verastem: Outlook For 2020-21

1 year ago - Seeking Alpha

Verastem: Still Bullish After Chugai Pharmaceutical Deal

1 year ago - Seeking Alpha

Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc.

1 year ago - GuruFocus

Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Verastem: Earnings Beat And Executing 6-2-5 Plan Trigger Unjustified Sell-Off

1 year ago - Seeking Alpha

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Verastem Oncology's share price continues to flatline as we approach the end of 2019. The market appears to have branded COPIKTRA's launch as a dud.

1 year ago - Seeking Alpha

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

1 year ago - Zacks Investment Research

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactin... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2012
CEO
Brian Stuglik
Employees
48
Stock Exchange
NASDAQ
Ticker Symbol
VSTM
Full Company Profile

Financial Performance

In 2020, Verastem's revenue was $88.52 million, an increase of 407.08% compared to the previous year's $17.46 million. Losses were -$67.73 million, -54.61% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Verastem stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 56.25% from the latest price.

Price Target
$4.50
(56.25% upside)
Analyst Consensus: Buy